RT Journal Article
SR Electronic
T1 Improving the assessment of embryo developmental potential via morphokinetic forecasting of future events using language modeling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.22.23297370
DO 10.1101/2023.10.22.23297370
A1 Zabari, Nir
A1 Kan-Tor, Yoav
A1 Srebnik, Naama
A1 Buxboim, Amnon
YR 2023
UL http://medrxiv.org/content/early/2023/10/23/2023.10.22.23297370.abstract
AB In IVF treatments, accurate assessment of the developmental potential of embryos to implant is essential for reaching reasonable pregnancy rates while shortening time-to-pregnancy. Hence, clinical guidelines recommend extended incubation to blastocyst transfers, which provide better evaluation of embryo developmental potential. However, cleavage stage transfer is often favored owing to various clinical considerations. To improve embryo assessment of cleavage stage embryos without extended incubation, we present a computational strategy for forecasting future morphokinetic events. Motivated by the advances in language modeling, we adapt generative pre-training to forecast future morphokinetic events based on the sequence of present events. We demonstrate < 12% forecasting error in forecasting up to three consecutive events. A new policy is proposed that combines morphokinetic forecasting and assessment of the risk of embryo developmental arrest. Using this policy, we demonstrate an improvement in the prediction of known implantation outcome of day-3 embryos from AUC 0.667 to 0.707. We expect morphokinetic forecasting to address the inherent hurdles in the selection of cleavage-stage embryos for transfer. In addition, we hope that demonstrating for the first time the utilization of language modeling on non-textual data in healthcare will stimulate future applications in reproductive medicine and other disciplines.Competing Interest StatementCompeting interests N.Z., N.S. and A.B. declare no financial or non-financial competing or other conflict of interest. Y.K.T. declares no financial or non-financial competing or other conflict of interest. Since September 2021, Y.K.T. discloses being employed by IBM-Research.Funding StatementA.B. greatly appreciates support from the European Research Council Proof of Concept Grant (PoC 966830) and the European Research Council Grant (ERC-StG 678977). The funders did not play any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Investigation Review Boards of the data-providing medical centers: Hadassah Hebrew University Medical center IRB number HMO 558-14; Kaplan Medical Center IRB 0040-16-KMC; Soroka Medical Center IRB 0328-17-SOR; Rabin Medical Center IRB 0767-15-RMC.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe copyrights of the code are owned by Yissum which is the technology transfer company of The Hebrew University of Jerusalem. Requests can be sent to A.B. The clinical data are owned by Hadassah Medical Center and by Clalit Health Services. Restrictions apply to the availability of these data, which were used anonymously under ethical agreements with each clinic separately for this study, and so are not made publicly available.